GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (NYSE:LLY) » Definitions » Piotroski F-Score

LLY (Eli Lilly and Co) Piotroski F-Score : 6 (As of Dec. 12, 2024)


View and export this data going back to 1970. Start your Free Trial

What is Eli Lilly and Co Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eli Lilly and Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Eli Lilly and Co's Piotroski F-Score or its related term are showing as below:

LLY' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Eli Lilly and Co was 8. The lowest was 4. And the median was 6.


Eli Lilly and Co Piotroski F-Score Historical Data

The historical data trend for Eli Lilly and Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Piotroski F-Score Chart

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 4.00 7.00 5.00

Eli Lilly and Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 5.00 5.00 4.00 6.00

Competitive Comparison of Eli Lilly and Co's Piotroski F-Score

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep24) TTM:Last Year (Sep23) TTM:
Net Income was 2189.7 + 2242.9 + 2967 + 970.3 = $8,370 Mil.
Cash Flow from Operations was -311.9 + 1166 + 1466.2 + 3711.9 = $6,032 Mil.
Revenue was 9353.4 + 8768 + 11302.8 + 11439.1 = $40,863 Mil.
Gross Profit was 7565.4 + 7094.5 + 9132.6 + 9268.3 = $33,061 Mil.
Average Total Assets from the begining of this year (Sep23)
to the end of this year (Sep24) was
(57915.5 + 64006.3 + 63943.5 + 71874.8 + 75606.9) / 5 = $66669.4 Mil.
Total Assets at the begining of this year (Sep23) was $57,916 Mil.
Long-Term Debt & Capital Lease Obligation was $29,045 Mil.
Total Current Assets was $31,415 Mil.
Total Current Liabilities was $24,674 Mil.
Net Income was 1937.7 + 1344.9 + 1763.2 + -57.4 = $4,988 Mil.

Revenue was 7301.8 + 6960 + 8312.1 + 9498.6 = $32,073 Mil.
Gross Profit was 5753.7 + 5333.3 + 6504.7 + 7638.5 = $25,230 Mil.
Average Total Assets from the begining of last year (Sep22)
to the end of last year (Sep23) was
(47461.5 + 49489.8 + 53163 + 54814 + 57915.5) / 5 = $52568.76 Mil.
Total Assets at the begining of last year (Sep22) was $47,462 Mil.
Long-Term Debt & Capital Lease Obligation was $17,924 Mil.
Total Current Assets was $23,007 Mil.
Total Current Liabilities was $21,998 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eli Lilly and Co's current Net Income (TTM) was 8,370. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eli Lilly and Co's current Cash Flow from Operations (TTM) was 6,032. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep23)
=8369.9/57915.5
=0.14451917

ROA (Last Year)=Net Income/Total Assets (Sep22)
=4988.4/47461.5
=0.10510414

Eli Lilly and Co's return on assets of this year was 0.14451917. Eli Lilly and Co's return on assets of last year was 0.10510414. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Eli Lilly and Co's current Net Income (TTM) was 8,370. Eli Lilly and Co's current Cash Flow from Operations (TTM) was 6,032. ==> 6,032 <= 8,370 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep23 to Sep24
=29045.4/66669.4
=0.43566314

Gearing (Last Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=17923.6/52568.76
=0.34095535

Eli Lilly and Co's gearing of this year was 0.43566314. Eli Lilly and Co's gearing of last year was 0.34095535. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep24)=Total Current Assets/Total Current Liabilities
=31415.1/24674.1
=1.27320145

Current Ratio (Last Year: Sep23)=Total Current Assets/Total Current Liabilities
=23007/21998.2
=1.0458583

Eli Lilly and Co's current ratio of this year was 1.27320145. Eli Lilly and Co's current ratio of last year was 1.0458583. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Eli Lilly and Co's number of shares in issue this year was 905.027. Eli Lilly and Co's number of shares in issue last year was 899.8. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=33060.8/40863.3
=0.8090585

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=25230.2/32072.5
=0.78666147

Eli Lilly and Co's gross margin of this year was 0.8090585. Eli Lilly and Co's gross margin of last year was 0.78666147. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep23)
=40863.3/57915.5
=0.70556759

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep22)
=32072.5/47461.5
=0.67575825

Eli Lilly and Co's asset turnover of this year was 0.70556759. Eli Lilly and Co's asset turnover of last year was 0.67575825. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+0+1+0+1+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eli Lilly and Co has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Eli Lilly and Co  (NYSE:LLY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Eli Lilly and Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Executives
Donald A Zakrowski officer: Chief Accounting Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Lilly Endowment Inc 10 percent owner 2801 NORTH MERIDIAN ST, INDIANAPOLIS IN 46208
Johna Norton officer: Senior VP, Global Quality LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Alonzo Weems officer: SVP, ERM & CECO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Patrik Jonsson officer: SVP and Pres., Lilly Bio-Meds LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Anne E. White officer: SVP & Pres-Lilly Oncology LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Eric Dozier officer: EVP, HR & Diversity LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Jackson P Tai director
Mary Lynne Hedley director C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Marschall S Runge director LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Naarden Jacob Van officer: SVP, CEO LoxoONC, Pres LlyONC C/O ELI LILLY & CO, LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Diogo Rau officer: SVP & CIDO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Edgardo Hernandez officer: SVP & Pres., Mfg. Operations LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Kimberly H Johnson director C/O FANNIE MAE, 1100 15TH STREET, NW, WASHINGTON DC 20005
Anat Ashkenazi officer: SVP & CFO LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285